2 results
Approved WMOCompleted
Primary:* To assess the safety and tolerability of LAM-001 administered daily by dry powder inhaler (DPI) for 14 days in patients with lymphangioleiomyomatosis (LAM) (Period 1).* To assess the longer-term safety and tolerability of LAM-001…
Approved WMOCompleted
To generate high quality empirical evidence for the effectiveness in terms of proportion of patients experiencing complications, quality of life and costs of initial non-operative treatment strategy (reserving appendectomies for those not responding…